73 related articles for article (PubMed ID: 19549771)
1. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Meyer T; Gaya AM; Dancey G; Stratford MR; Othman S; Sharma SK; Wellsted D; Taylor NJ; Stirling JJ; Poupard L; Folkes LK; Chan PS; Pedley RB; Chester KA; Owen K; Violet JA; Malaroda A; Green AJ; Buscombe J; Padhani AR; Rustin GJ; Begent RH
Clin Cancer Res; 2009 Jul; 15(13):4484-92. PubMed ID: 19549771
[TBL] [Abstract][Full Text] [Related]
2. Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice.
Sato N; Saga T; Sakahara H; Nakamoto Y; Zhao S; Kuroki M; Iida Y; Endo K; Konishi J
Jpn J Cancer Res; 2000 Jun; 91(6):622-8. PubMed ID: 10874215
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies.
Akhavan D; Yazaki P; Yamauchi D; Simpson J; Frankel PH; Bading J; Colcher D; Poku K; Chen YJ; Lim D; Cristea M; Wu A; Shively J; Wong JYC
Cancer Biother Radiopharm; 2020 Feb; 35(1):10-15. PubMed ID: 31910346
[No Abstract] [Full Text] [Related]
4. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Nathan P; Zweifel M; Padhani AR; Koh DM; Ng M; Collins DJ; Harris A; Carden C; Smythe J; Fisher N; Taylor NJ; Stirling JJ; Lu SP; Leach MO; Rustin GJ; Judson I
Clin Cancer Res; 2012 Jun; 18(12):3428-39. PubMed ID: 22645052
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections.
Liu P; Qin Y; Wu L; Yang S; Li N; Wang H; Xu H; Sun K; Zhang S; Han X; Sun Y; Shi Y
Anticancer Drugs; 2014 Apr; 25(4):462-71. PubMed ID: 24500030
[TBL] [Abstract][Full Text] [Related]
6. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
7. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
Lin CM; Singh SB; Chu PS; Dempcy RO; Schmidt JM; Pettit GR; Hamel E
Mol Pharmacol; 1988 Aug; 34(2):200-8. PubMed ID: 3412321
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.
Ng QS; Mandeville H; Goh V; Alonzi R; Milner J; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Ann Oncol; 2012 Jan; 23(1):231-237. PubMed ID: 21765046
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors.
Lin B; Du H; Fan J; Huang D; Gao F; Li J; Zhang Y; Feng G; Dai T; Du X
Front Oncol; 2021; 11():750741. PubMed ID: 34745976
[TBL] [Abstract][Full Text] [Related]
10. Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis.
Chappell DL; White MC; Damania B
Adv Virus Res; 2021; 109():201-254. PubMed ID: 33934828
[TBL] [Abstract][Full Text] [Related]
11. Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.
Lorza AMA; Ravi H; Philip RC; Galons JP; Trouard TP; Parra NA; Von Hoff DD; Read WL; Tibes R; Korn RL; Raghunand N
Sci Rep; 2020 Sep; 10(1):14449. PubMed ID: 32879326
[TBL] [Abstract][Full Text] [Related]
12. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.
Liu Y; Wang S; Zhao X; Feng Y; Bormans G; Swinnen J; Oyen R; Huang G; Ni Y; Li Y
Diagnostics (Basel); 2020 Jan; 10(2):. PubMed ID: 32024029
[TBL] [Abstract][Full Text] [Related]
13. A Novel Microtubule-Binding Drug Attenuates and Reverses Protein Aggregation in Animal Models of Alzheimer's Disease.
Kakraba S; Ayyadevara S; Penthala NR; Balasubramaniam M; Ganne A; Liu L; Alla R; Bommagani SB; Barger SW; Griffin WST; Crooks PA; Shmookler Reis RJ
Front Mol Neurosci; 2019; 12():310. PubMed ID: 31920540
[TBL] [Abstract][Full Text] [Related]
14. A Dual Reporter Iodinated Labeling Reagent for Cancer Positron Emission Tomography Imaging and Fluorescence-Guided Surgery.
Lu Z; Pham TT; Rajkumar V; Yu Z; Pedley RB; Årstad E; Maher J; Yan R
J Med Chem; 2018 Feb; 61(4):1636-1645. PubMed ID: 29388770
[TBL] [Abstract][Full Text] [Related]
15. Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen.
Shinmi D; Nakano R; Mitamura K; Suzuki-Imaizumi M; Iwano J; Isoda Y; Enokizono J; Shiraishi Y; Arakawa E; Tomizuka K; Masuda K
Cancer Med; 2017 Apr; 6(4):798-808. PubMed ID: 28211613
[TBL] [Abstract][Full Text] [Related]
16. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
Liang W; Ni Y; Chen F
Oncotarget; 2016 Mar; 7(13):15444-59. PubMed ID: 26812886
[TBL] [Abstract][Full Text] [Related]
17. Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.
Shao H; Zhang J; Sun Z; Chen F; Dai X; Li Y; Ni Y; Xu K
Oncotarget; 2015 Jun; 6(16):14247-59. PubMed ID: 26036625
[TBL] [Abstract][Full Text] [Related]
18. Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response.
Rajkumar V; Goh V; Siddique M; Robson M; Boxer G; Pedley RB; Cook GJ
Br J Cancer; 2015 Jun; 112(12):1882-7. PubMed ID: 25989271
[TBL] [Abstract][Full Text] [Related]
19. uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
Boonstra MC; van Driel PB; van Willigen DM; Stammes MA; Prevoo HA; Tummers QR; Mazar AP; Beekman FJ; Kuppen PJ; van de Velde CJ; Löwik CW; Frangioni JV; van Leeuwen FW; Sier CF; Vahrmeijer AL
Oncotarget; 2015 Jun; 6(16):14260-73. PubMed ID: 25895028
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Kawashima H
ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
